ReviewInternational journal of nanomedicine2012
Progress on RNAi-based molecular medicines.
Review in International journal of nanomedicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- GABPB1 plays a cancer-promoting role in non-small cell lung cancer.Discover oncology · 2024Article
- Role of miRNAs in Neurodegeneration: From Disease Cause to Tools of Biomarker Discovery and Therapeutics.Genes · 2022Review
- MicroRNAs in Neuroinflammation: Implications in Disease Pathogenesis, Biomarker Discovery and Therapeutic Applications.Non-coding RNA · 2019Review
- Review
- Latest development on RNA-based drugs and vaccines.Future science OA · 2018Review
- Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia.Molecular therapy. Nucleic acids · 2017Article
- Transarterial embolization combined with RNA interference targeting hypoxia-inducible factor-1α for hepatocellular carcinoma: a preliminary study of rat model.Journal of cancer research and clinical oncology · 2017Article
- Design, synthesis and evaluation of VEGF-siRNA/CRS as a novel vector for gene delivery.Drug design, development and therapy · 2016Article
- RNA-based drugs and vaccines.Expert review of vaccines · 2015Review
- Article
- Ultrasound-guided RNA interference targeting HIF-1 alpha improves the effects of transarterial chemoembolization in rat liver tumors.OncoTargets and therapy · 2015Article
- Engineered RNA Nanodesigns for Applications in RNA Nanotechnology.DNA and RNA nanotechnology · 2015Article
- Multifunctional RNA nanoparticles.Nano letters · 2014Article
- Array-based genome-wide RNAi screening to identify shRNAs that enhance p53-related apoptosis in human cancer cells.Oncotarget · 2014Article
- Gold nanoparticles for nucleic acid delivery.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Review
- Introduction of mismatches in a random shRNA-encoding library improves potency for phenotypic selection.PloS one · 2014Article
- Evaluation of single and dual siRNAs targeting rabies virus glycoprotein and nucleoprotein genes for inhibition of virus multiplication in vitro.Archives of virology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RNA interference (RNAi) is a promising strategy to suppress the expression of disease-relevant genes and induce post-transcriptional gene silencing. Their simplicity and stability endow RNAi with great advantages in molecular medicine. Several RNAi-based drugs are in various stages of clinical investigation. This review summarizes the ongoing research endeavors on RNAi in molecular medicine, delivery systems for RNAi-based drugs, and a compendium of RNAi drugs in different stages of clinical development. Of special interest are RNAi-based drug target discovery and validation, delivery systems for RNAi-based drugs, such as nanoparticles, rabies virus protein-based vehicles, and bacteriophages for RNA packaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.